CMMS in Life Sciences is Different with Chris Tencza

In this CMMSradio episode, CMMSradio talks with Chris Tencza of Blue Mountain about why Computerized Maintenance Management Systems (CMMS) and Enterprise Asset Management (EAM) work very differently in the highly regulated life sciences industry (pharma, biotech, medical devices, cell & gene therapy, etc.).Why life sciences is uniqueIn regulated manufacturing, a maintenance record isn’t just an operational tool — it is audit evidence. Compliance (GxP, 21 CFR Part 11, GAMP 5, etc.) is non-negotiable. Generic, horizontal CMMS platforms often force companies into heavy customization and lengthy validation cycles, creating risk and cost.Purpose-built vs. adapted systemsBlue Mountain’s Regulatory Asset Manager (RAM) was designed from the ground up for life sciences rather than adapted from a general-purpose system. It combines maintenance, calibration, and asset management in one validated platform with pre-configured, inspection-ready workflows.Practical advantages Faster implementation and lower validation burden Built-in electronic signatures, audit trails, and data integrity Better support for multi-site operations and ongoing compliance Ability to stay closer to out-of-the-box validated functionality (reducing revalidation costs)Chris draws on decades of hands-on experience in maintenance, reliability, calibration, and CMMS implementation in both food and life sciences environments. The conversation emphasizes that in this industry, the right CMMS is not just about efficiency — it is a core part of the compliance infrastructure that protects product quality and patient safety.Bottom line: What works in general manufacturing often falls short in life sciences. A purpose-built, validated solution makes a measurable difference in risk, cost, and inspection readiness.